Evofem Biosciences, Inc.

EVFMSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1618835

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$19.4M	$18.2M	$16.8M	—	—
Cost of Goods and Services Sold	$3.8M	$6.5M	$4.4M	$4.1M	$468.0K
Research and Development Expense	—	$2.9M	$25.0M	$33.1M	$17.1M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$7.7M	-$17.8M	-$84.1M	-$166.8M	-$103.6M
Interest Expense	$2.2M	$2.3M	$2.2M	$2.7M	$2.1M
Nonoperating Income (Expense)	-$1.2M	$70.8M	$7.5M	-$38.4M	-$38.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$23.8M	$10.6M	$25.2M	$42.5M	$110.0M
Assets, Current	$13.6M	$9.2M	$12.7M	$30.1M	$97.7M
Cash and Cash Equivalents, at Carrying Value	$741.0K	—	$2.8M	$7.7M	$48.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$9.8M	$5.7M	$1.1M	$6.4M	$1.1M
Inventory, Net	$1.6M	$1.7M	$5.4M	$7.7M	$7.2M
Liabilities	$90.3M	$72.5M	$97.0M	$142.1M	$108.6M
Liabilities, Current	$80.4M	$72.5M	$93.8M	$137.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$3.9M	-$9.0M	-$70.4M	-$146.7M	-$104.8M
Net Cash Provided by (Used in) Investing Activities	-$569.0K	-$4.0K	-$341.0K	-$2.7M	$6.2M
Net Cash Provided by (Used in) Financing Activities	$4.6M	$4.8M	$61.9M	$90.7M	$154.2M
Payments to Acquire Property, Plant, and Equipment	$14.0K	$4.0K	$341.0K	$2.9M	$2.3M
Payments of Dividends	—	—	—	—	—
Payments for Repurchase of Common Stock	—	—	$18.0K	$0.00	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)